Professional Documents
Culture Documents
Purpose of review
Chronic obstructive pulmonary disease (COPD) and heart failure are prevalent
comorbidities affecting a huge proportion of the world population, responsible for
significant morbidity and mortality. Their coexistence is more frequent than previously
recognized and poses important diagnostic and therapeutic challenges. Prognosis of
patients with concurrent heart failure and COPD has not been comprehensively
addressed. With this review, we intend to emphasize the diagnosis and prognosis
implications of the two coexisting conditions and to highlight the therapeutic constraints
posed by the combination.
Recent findings
Progressively, more attention has been given to the interplay between COPD and heart
failure. The combination is frequent, but largely unrecognized due to overlapping clinical
manifestations. Patients presenting with both conditions seem to have an ominous
course. Despite the overwhelming evidence supporting cardioselective b-blockade
safety and tolerability in COPD patients, b-blockers are underprescribed to heart failure
patients with concomitant COPD.
Summary
COPD and heart failure coexistence is often overlooked. COPD diagnosis can remain
unsuspected in heart failure patients due to similar symptoms. Although b-blockers are
well tolerated in COPD patients, they are overall less prescribed in this challenging
population. COPD, at least at severe degrees of airflow obstruction, predicts a worse
prognosis in heart failure patients.
Keywords
b-blockers, chronic obstructive pulmonary disease, heart failure, prognosis
Curr Opin Pulm Med 16:106111
2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
1070-5287
Introduction
Heart failure and chronic obstructive pulmonary disease
(COPD) are major public health epidemics, with increasing prevalence [1,2,3]. Although both conditions
have been extensively studied separately, clinicians
often fail to recognize one syndrome in the presence
of the other, mainly due to the similarities in clinical
presentation and additionally due to scarcity of reports
specifically addressing the combination [4]. According to
available evidence, COPD and heart failure often coexist, and the prevalence of the combination is variable,
depending on the population studied (community, outpatient or hospitalized) and on the diagnostic criteria
applied [4,5]. The coexistence of the two conditions is
further supported by shared risk factors, notably age and
smoking [1,5,6].
Since the publication of several trials demonstrating the
efficacy and the survival benefits of b-blockers, these
1070-5287 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
1.0
++
+++
+
+
+++
0.8
++
++++
++
++ +
++ +
+ ++
++
+
+
+
++ +
0.6
+
+
++ +
+
++ +
+
P = 0.16
+
++
+
0.4
COPD
0.2
No
Yes
0.0
0.00
200.00
400.00
600.00
800.00
Time (days)
COPD, chronic obstructive pulmonary disease. Reproduced with permission from [27].
1.0
++
+++
+
++ ++
+++
+
+ +++
+
0.8
+ + +
+ ++
++
+
+
+
++
+++
0.6
++ +
+ ++
+
++
0.4
+ ++
GOLD stages
0
I
II
III/IV
0.2
0.036
0.0
0.00
200.00
400.00
600.00
800.00
Time (days)
Stage I: HR 1.06 (95% CI 0.472.37); stage II: HR 1.31 (95% CI 0.72
2.38); stages III and IV: HR 2.10 (95% CI 1.054.22). CI, confidence
interval; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
HR, hazard ratio. Reproduced with permission from [27].
Conclusion
The coexistence of COPD and heart failure is frequent,
but commonly ignored. The diagnosis of one condition
in the presence of the other is challenging and requires
objective evidence of pulmonary and cardiac dysfunction, apart from the appropriate clinical picture.
Although long-term effects of b-blockers need to be
further assessed in COPD patients, these agents are
currently recommended in all heart failure patients
with concurrent COPD. Despite this, prescription
rates remain disappointingly low mainly because of
concerns related to bronchospasm. It is generally
acknowledged that COPD adversely affects heart
failure prognosis, although more conclusive studies
are still needed.
Considering the expanding mortality and the profound
impact on quality of life and performance status imposed
by each disease, it is crucial to diagnose these two
coexistent conditions and to establish a management
strategy that simultaneously addresses both comorbidities in order to alleviate symptoms, delay progression and
improve prognosis.
GOLD, Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive
pulmonary disease: NHLBI/WHO workshop report 2006. http://www.gold
copd.com/.
2
Rutten FH, Cramer MJ, Lammers JW, et al. Heart failure and chronic
obstructive pulmonary disease: an ignored combination? Eur J Heart Fail
2006; 8:706711.
Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive
pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail
2009; 11:130139.
This study extensively reviews the prevalence of COPD in heart failure patients and
the diagnostic and prognostic implications posed by the combination.
5
Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the
prevalence of COPD (The BOLD Study): a population-based prevalence
study. Lancet 2007; 370:741750.
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity
and mortality in patients with chronic heart failure. US Carvedilol Heart Failure
Study Group. N Engl J Med 1996; 334:13491355.